Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors.

  title={Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors.},
  author={Andrea Pession and Arcangelo Prete and Francesco Locatelli and S Bella and Fraia Melchionda and Alberto Garaventa and Roberta Burnelli and G. Paolucci},
  journal={Medical and pediatric oncology},
  volume={33 5},
BACKGROUND The aim of this phase I study was to define the maximum tolerated dose (MTD) of thiotepa (TT), administered with busulfan (BU) 480 mg/m(2) and etoposide 2,400 mg/m(2), followed by autologous bone marrow transplantation (ABMT) or peripheral blood stem cell transplantation (APBSCT) support in children with solid tumors either disseminated at diagnosis or after relapse. PROCEDURE Nineteen patients, between 2 and 16 years of age, received a high-dose chemotherapy regimen including… 

High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma

High-dose chemotherapy with thiotepa, etoposide and carboplatin may represent a curative option for children with extrabulbar or disseminated retinoblastoma responsive to chemotherapy and may control occult CNS disease.

High-dose chemoradiotherapy (HDC) in the Ewing family of tumors (EFT).

High-dose chemotherapy for children and young adults with stage IV rhabdomyosarcoma.

The results of this review do not justify the use of HDC with SCR as a standard therapy for children with metastatic rhabdomyosarcoma and a clinically important excess of adverse risk patients in the HDC arms may explain the non-beneficial effect ofHDC.

Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for nonrhabdomyosarcoma soft tissue sarcomas.

To assess the efficacy and safety of high-dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (HSCT) for all stages of nonrhabdomyosarcoma soft tissue sarcomas (NRSTS) in children and adults, a search strategy to improve the precision and reduce the number of irrelevant hits was revised.

Hematopoietic stem cell transplantation in childhood: report from the bone marrow transplantation group of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).

These data reflect the development and present status of HSCT in Italy and provide a basis for patient counseling and health care planning.

HLA-mismatched hematopoietic stem cell tranplantation for pediatric solid tumors

An experimental study design of HLA-mismatched HSCT for the treatment of pediatric solid tumors and the inherent preliminary results are reported.

Ewing Tumour

Treatment of patients with Ewing tumours should be performed in experienced centres only and preferably within controlled clinical trials, and inclusion of high-risk patients in phase I and II studies is warranted.

Pharmacometric modelling of processes in the haematopoietic system and blood

The objective of this thesis was to contribute to the understanding and characterisation of proliferation, maturation and ageing processes of haematopoietic progenitor and blood cells applying the

A high-dose busulfan-thiotepa combination followed by autologous bone marrow transplantation in childhood recurrent ependymoma. A phase-II study.

Sixteen children with refractory or relapsed ependymoma were entered in a phase-II study of high-dose chemotherapy followed by autologous bone marrow transplantation (ABMT), andEpendymomas do not appear to be sensitive to this combination therapy.

Thiotepa and etoposide treatment of recurrent malignant gliomas: phase I study

The maximum tolerable dose of thiotepa (TT) that can be administered with etoposide without stem cell support is 60 mg/m2, and this regimen is active against recurrent malignant gliomas.

A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma.

A conditioning regimen consisting of 500 mg/m2 etoposide, thiotepa, and 1200 cGy fractionated total body irradiation and fTBI has acceptable toxicity and is at least as effective as melphalan-containing regimens in the treatment of high-risk NBL.

A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies

The combination of high-dose CPA, cDDP, and thio TEPA is a well-tolerated regimen when thioTEPA is given prior to CPA and cD DP and when the combination also includes PBPCs in addition to ABM, which is active in a variety of malignancies.

Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group.

  • J. FinlayS. Goldman R. Packer
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1996
The combination of high-dose thiotepa and etoposide has activity against a variety of recurrent childhood brain tumors, and survival was significantly improved in patients treated with minimal residual disease.

Disposition of high‐dose busulfan in pediatric patients undergoing bone marrow transplantation

The half‐lives for busulfan during infancy decrease continuously until early childhood but were prolonged in older children, and no significant relationship between systemic exposure toBusulfan and drug effect was observed.

High-dose N,N',N"-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies.

High-dose thiotepa appears to be an alkylating agent with broad-spectrum antitumor efficacy, which should add to the cytoreductive regimens for both solid and hematopoietic tumors.

Bone marrow autotransplantation for solid tumors--prospects.

Experimental and preliminary clinical evidence as marshalled in this review indicate that autologous bone marrow transplantation is a promising area for therapeutic research.

Hepatic veno-occlusive disease--liver toxicity syndrome after bone marrow transplantation.

Analysis of morphologic and biochemical data support the hypothesis that VOD is caused by cytoreductive injury to hepatocytes and endothelium in zone three of the liver acinus, and in turn strongly influenced by factors which induce the release of tumor necrosis factor-alpha (TNF-alpha) leading to enhancement or activation of coagulation with obstruction of hepatic sinusoids and venules.